Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701587 | 1.00 | LMNA (0.58) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL2142734 | 1.00 | LMNA (0.58) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL13618128 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL14617628 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL2525369 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL2525365 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL14019069 | 0.87 | LMNA (0.66) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL5019087 | 0.87 | LMNA (0.61) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL8132360 | 0.85 | CTSS (0.53) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL8274264 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2HTTCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2007057756-A2 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057767-A2 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| US-4237269-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-12-02 | — | — | US | disclosed |
| US-4231945-A | BACTERICIDES | SCHERING CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4212860-A | COUPLING THE PENTOFURANOSYL ONTO THE PROTECTED CYCLITOL | SCHERING CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227680-A1 | Amino Acid Derivatives | OPRL1, OPRK1, AVPR1A | LMNA 3623/4885SMN1; SMN2 1720/4885HTT 1869/4885 |
| US-20090286875-A1 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN | IDH3A, ACHE, SDHA | LMNA 3329/4885SMN1; SMN2 1529/4885HTT 1291/4885 |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3293/4885SMN1; SMN2 3973/4885HTT 1626/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3293/4885SMN1; SMN2 3973/4885HTT 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.